142 related articles for article (PubMed ID: 23587588)
1. [Imatinib plasma levels in the management of cutaneous side effects induced by imatinib (Glivec®): 2 case reports].
Trabelsi S; Gaïes E; Sraïri S; Sahnoun R; Daghfous R; Lakhal M; El Aïdli S; Klouz A
Ann Biol Clin (Paris); 2013; 71(2):203-6. PubMed ID: 23587588
[TBL] [Abstract][Full Text] [Related]
2. A patient of chronic myelogenous leukemia developing painful rash on feet.
Kumar P; Das NK; Sil A; Chakrabarti P
J Postgrad Med; 2012; 58(4):331-4. PubMed ID: 23298941
[No Abstract] [Full Text] [Related]
3. Severe pustular eruption associated with imatinib and voriconazole in a patient with chronic myeloid leukemia.
Gambillara E; Laffitte E; Widmer N; Decosterd LA; Duchosal MA; Kovacsovics T; Panizzon RG
Dermatology; 2005; 211(4):363-5. PubMed ID: 16286749
[TBL] [Abstract][Full Text] [Related]
4. Successful progressive challenge after a cutaneous reaction to imatinib mesylate (Gleevec): a case report and review of the literature.
Park MA; Volcheck GW; Guarderas JC
Allergy Asthma Proc; 2004; 25(5):345-7. PubMed ID: 15603208
[TBL] [Abstract][Full Text] [Related]
5. Imatinib mesylate-induced pseudoporphyria in two children.
Mahon C; Purvis D; Laughton S; Bradbeer P; Teague L
Pediatr Dermatol; 2014; 31(5):603-7. PubMed ID: 24920470
[TBL] [Abstract][Full Text] [Related]
6. Correlation of plasma trough levels of imatinib with molecular response in patients with chronic myeloid leukemia.
Malhotra H; Sharma P; Bhargava S; Rathore OS; Malhotra B; Kumar M
Leuk Lymphoma; 2014 Nov; 55(11):2614-9. PubMed ID: 24446903
[TBL] [Abstract][Full Text] [Related]
7. Heliotrope-like eruption mimicking dermatomyositis in a patient treated with imatinib mesylate for chronic myeloid leukemia.
Kuwano Y; Asahina A; Watanabe R; Fujimoto M; Ihn H; Tamaki K
Int J Dermatol; 2006 Oct; 45(10):1249-51. PubMed ID: 17040457
[No Abstract] [Full Text] [Related]
8. Pseudoporphyria induced by imatinib mesylate.
Pérez NO; Esturo SV; Viladomiu Edel A; Moreno AJ; Valls AT
Int J Dermatol; 2014 Feb; 53(2):e143-4. PubMed ID: 23451912
[No Abstract] [Full Text] [Related]
9. Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients.
Valeyrie L; Bastuji-Garin S; Revuz J; Bachot N; Wechsler J; Berthaud P; Tulliez M; Giraudier S
J Am Acad Dermatol; 2003 Feb; 48(2):201-6. PubMed ID: 12582389
[TBL] [Abstract][Full Text] [Related]
10. Periungual pyogenic granuloma following imatinib therapy in a patient with chronic myelogenous leukemia.
Dika E; Barisani A; Vaccari S; Fanti PA; Ismaili A; Patrizi A
J Drugs Dermatol; 2013 May; 12(5):512-3. PubMed ID: 23652942
[No Abstract] [Full Text] [Related]
11. Cutaneous reactions to STI571.
Brouard M; Saurat JH
N Engl J Med; 2001 Aug; 345(8):618-9. PubMed ID: 11529225
[No Abstract] [Full Text] [Related]
12. Vocal fold hemorrhage in a CML patient after Glivec treatment.
Shim HS; Woo SH
Acta Oncol; 2013 May; 52(4):866-8. PubMed ID: 23153030
[No Abstract] [Full Text] [Related]
13. Lichenoid drug eruption with palmoplantar hyperkeratosis due to imatinib mesylate: a case report and a review of the literature.
Kuraishi N; Nagai Y; Hasegawa M; Ishikawa O
Acta Derm Venereol; 2010; 90(1):73-6. PubMed ID: 20107730
[TBL] [Abstract][Full Text] [Related]
14. No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia.
Racil Z; Razga F; Klamova H; Voglova J; Belohlavkova P; Malaskova L; Potesil D; Muzik J; Zackova D; Polakova KM; Zdrahal Z; Malakova J; Suttnar J; Dyr J; Mayer J
Hematol Oncol; 2014 Jun; 32(2):87-93. PubMed ID: 23963760
[TBL] [Abstract][Full Text] [Related]
15. Imatinib: a designer drug, another cutaneous complication.
Dickens E; Lewis F; Bienz N
Clin Exp Dermatol; 2009 Jul; 34(5):603-4. PubMed ID: 19486036
[TBL] [Abstract][Full Text] [Related]
16. Plasma and intracellular imatinib concentrations in patients with chronic myeloid leukemia.
De Francia S; DʼAvolio A; Ariaudo A; Pirro E; Piccione F; Simiele M; Fava C; Calcagno A; Di Perri G; Saglio G
Ther Drug Monit; 2014 Jun; 36(3):410-2. PubMed ID: 24342895
[TBL] [Abstract][Full Text] [Related]
17. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.
Cohen MH; Williams G; Johnson JR; Duan J; Gobburu J; Rahman A; Benson K; Leighton J; Kim SK; Wood R; Rothmann M; Chen G; U KM; Staten AM; Pazdur R
Clin Cancer Res; 2002 May; 8(5):935-42. PubMed ID: 12006504
[TBL] [Abstract][Full Text] [Related]
18. [Drug reaction with eosinophilia and systemic symptoms (DRESS) following imatinib therapy].
Le Nouail P; Viseux V; Chaby G; Billet A; Denoeux JP; Lok C
Ann Dermatol Venereol; 2006; 133(8-9 Pt 1):686-8. PubMed ID: 17053739
[TBL] [Abstract][Full Text] [Related]
19. Multiple eruptive dermatofibromas related to imatinib treatment.
Llamas-Velasco M; Fraga J; Solano-López GE; Steegmann JL; García Diez A; Requena L
J Eur Acad Dermatol Venereol; 2014 Jul; 28(7):979-81. PubMed ID: 24321053
[No Abstract] [Full Text] [Related]
20. Imatinib-induced Stevens-Johnsons syndrome.
Jha P; Himanshu D; Jain N; Singh AK
BMJ Case Rep; 2013 Jan; 2013():. PubMed ID: 23349042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
